Naomi Fried

Co-founder & Managing Partner

2024

PharmStars Ventures is an innovative venture fund that complements the PharmStars accelerator (www.pharmstars.com), the premier, global pharma-digital health accelerator. Over the last four years, PharmStars has sourced, selected, and accelerated more than 79 cutting-edge startups, fostering innovation in pharmatech. PharmStars Ventures builds on this experience by strategically investing in the accelerator's graduates. With a focus on bridging the gap between pharma and digital health startups, the fund leverages established industry connections, rigorous due diligence, PharmStars’ unique PharmaU curriculum, and long-term development programs to drive the adoption of transformative solutions and improve patient outcomes.

Member of the Board of Advisors

2024

o Panacea-ml revolutionizes clinical trial design with its data-driven, explainable-AI SaaS platform. Its cutting-edge AI technology addresses the primary causes of clinical development failure by identifying patient profiles that maximize therapeutic efficacy, minimize safety risks, and improve participant retention. Leveraging historical clinical trials and over 1 million real-world patient health records, Panacea-ml's AI model enhances patient selection criteria, reduces cohort sizes, and uncovers novel marker-endpoint interrelations, surrogate markers, and causal relationships beyond simple statistical correlations

Founder and CEO

2021

Managing Partner and Co-Founder

2020

Investing in early-stage "must-have" digital health innovations

Board Member

2022

Head Diagnostics is developing innovative technology and an associated handheld medical device for the diagnosis of concussion (mTBI) and Parkinson’s Disease (PD). This novel technology will provide for rapid assessment and assist clinicians in making objective diagnoses of brain disease and brain impairment.

Member Board Of Directors

2021

Advisory Board Member

2022 - 2024

Industry Advisory Board Member

2019 - 2022

Industry Advisory Board Member of this leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease until acquisition by Pfizer. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnea in a double-blind, prospective clinical study.

Advisory Board Member

2017 - 2020

Advisory board member to this leading digital health start-up that diagnoses neurodegenerative diseases non-invasively using a proprietary algorithms for analyzing typing patterns.

Founder and CEO

2016 - 2020

Providing digital health strategy and innovation infrastructure management consulting services to a range of healthcare clients including, pharma, providers and start-ups. Recent Consulting Engagement: ♦ Roche Pharmaceuticals: Advising on digital healthcare and digital-knowledge management strategy. Creating strategic frameworks for building competencies and capabilities for a robust digital health program. Advising client on potential innovative digital health pilot projects to address unmet needs in various therapeutic areas. ♦Children's Hospital of Los Angeles: Development of a strategic plan for a robust, enterprise innovation program. Providing strategic guidance on program vision, goals, programs, structure, organization, staffing, and budgets. ♦Merck, Roche and others: Advice on emerging trends in healthcare innovation and digital health in the pharmaceutical industry.